Harrow, Inc. (HROW) Earnings Call Analysis
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Earnings Reports
-
Harrow (HROW) Q1 2026: VEVY Net Pricing Reset Lifts Outlook as Demand Surges 25%
May 12, 2026
-
HROW Q4 2025: Vivi Revenue Jumps 216% as Sales Force Doubles to Target Market Leadership
March 03, 2026
-
Harrow (HROW) Q3 2025: Vivi Market Share Doubles, Unlocking Payer-Driven Upside for 2026
November 11, 2025
-
Harrow (HROW) Q2 2025: TriEssence Up 32% as Ophthalmic Portfolio Accelerates Leverage
August 12, 2025
-
Harrow (HROW) Q1 2025: Vivi Revenue Jumps 35% as Access Program Accelerates Prescription Growth
July 06, 2025